European Medicines Agency validates submission of MAA for Nidlegy
Nidlegy is partnered with Sun Pharma for the treatment of Skin Cancers in Europe, New Zealand and Australia. Both companies jointly made the following announcements:
– 23 October 2023 – Phase III PIVOTAL trial met the primary endpoint
– 31 May 2024 – Primary results of PIVOTAL presented at ASCO
– 04 June 2024 – MAA submission to EMA
The data of the Phase III Nidlegy trial are expected to be published in a peer-reviewed scientific journal in 2024.
Powered by Capital Market – Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
First Published: Jul 04 2024 | 3:04 PM IST
Related
European markets fall and euro soars amid Trump tariff delays
European stock markets have slumped after Donald Trump’s second reversal on tariffs caused deep uncertainty among investors, while the euro was on track for i
European Central Bank cuts interest rates, keeps door ajar to…
Open this photo in gallery:The European Central Bank headquarters, in Frankfurt, Germany, on June 6, 2024.Wolfgang Rattay/ReutersThe European Central Bank cut i
European security, economy without Türkiye ‘impossible,’ says business leader –…
ISTANBUL Türkiye’s strategic importance for Europe's future is both undeniable and multifaceted, encompassing critical areas suc
Westcon-Comstor promotes Rene Klein to lead unified European business
Westcon-Comstor has announced the appointment of Rene Klein as executive vice president for EMEA, tasked with leading the company’s new unified leadership st
